New drug combo aims to shrink prostate tumors before surgery

NCT ID NCT06613100

Recruiting now Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This early-stage trial is testing a drug called xaluritamig, given alone or with a hormone blocker, before men with intermediate- or high-risk prostate cancer have their prostate removed. The main goal is to see if the treatment is safe and does not interfere with surgery. About 40 men will take part, and researchers will also look at how the drug affects PSA levels and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: xaluritamig (a drug given by IV) and a GnRH antagonist (oral hormone blocker)
What this could lead to: If it works, this could point toward a way to shrink prostate tumors before surgery, potentially improving outcomes for men with aggressive prostate cancer.
What could go wrong: This is a very early (Phase 1) study with only 40 participants, so it is mainly checking safety and feasibility—not yet testing if it truly works. Side effects from the drugs or surgery complications are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALIZED INTERMEDIATE OR HIGH-RISK PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Carolina Urologic Research Center
RECRUITING

Myrtle Beach, South Carolina, 29572, United States
Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109-1023, United States
Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States
The Ohio State University
RECRUITING

Columbus, Ohio, 43210, United States
Thomas Jefferson University
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
Universitaetsklinikum Essen
RECRUITING

Essen, 45147, Germany
Universitaetsklinikum Hamburg Eppendorf
RECRUITING

Hamburg, 20246, Germany
University of California San Francisco
RECRUITING

San Francisco, California, 94143, United States
Washington University
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.